Close Menu

Somalogic

The trials will evaluate biomarker panels for lung, colon, and prostate cancer, and may include a comparison of proteomics-based lung cancer tests from Somalogic and Celera.

The company released results from studies of its six-protein diagnostic panel for lung cancer at this month's AACR meeting and this summer may take part in a 300-patient trial sponsored by the NCI's Early Detection Research Network.

In a study involving 38 mesothelioma patients and 62 asbestos-exposed controls, the 13-protein panel distinguished between the two with a sensitivity and specificity of 92 percent, said one of the researchers.

Life Technologies, Takara Shuzo, SomaLogic, and the University of California are awarded US patents.

IP Roundup: Dec 21, 2010

Premium

The United States of America, SomaLogic, Samsung Electronics, University of North Carolina

The test is intended both for early screening purposes and the differential diagnoses of lung nodules detected during CT scans and x-rays. SomaLogic has partnered with Quest Diagnostics to commercialize the test, with a lab-developed version slated for launch next year.

Companies developing array- or biochip-based molecular diagnostics received a shot in the arm earlier this month under the Internal Revenue Service's $1 billion Qualifying Therapeutic Discovery Project program.

A number of prominent proteomics-based diagnostics developers were recipients of the grant and tax credit awards, which are being provided by the IRS through the Patient Protection and Affordable Care Act's Qualifying Therapeutic Discovery Project Program.

The validation trials will each involve on the order of 400 patients and should be completed within a year, said a company official.

The agreement with NEC, which has purchased an equity stake in the company, is part of its plan to expand beyond its traditional focus on biomarker discovery and diagnostics development to become a "health information company" that can "provide actionable medical information to patients, physicians, and researchers," said an official.

Pages

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.